100 Clinical Results associated with Amino acids/calcium acetate/glycerin/magnesium acetate/phosphoric acid/potassium chloride/sodium acetate/sodium chloride

100 Translational Medicine associated with Amino acids/calcium acetate/glycerin/magnesium acetate/phosphoric acid/potassium chloride/sodium acetate/sodium chloride

100 Patents (Medical) associated with Amino acids/calcium acetate/glycerin/magnesium acetate/phosphoric acid/potassium chloride/sodium acetate/sodium chloride

Literatures (Medical) associated with Amino acids/calcium acetate/glycerin/magnesium acetate/phosphoric acid/potassium chloride/sodium acetate/sodium chloride

01 May 2015·Journal of Veterinary Emergency and Critical CareQ3 · AGRICULTURAL & FORESTRY SCIENCE

Retrospective evaluation of ProcalAmine administration in a population of hospitalized ICU dogs: 36 cases (2010–2013)

Q3 · AGRICULTURAL & FORESTRY SCIENCE

Article

Author: Olan, Natasha V. ; Prittie, Jennifer

AbstractObjectiveTo describe the use of ProcalAmine as a source of parenteral nutrition in hospitalized dogs and to report complications possibly referable to its use.DesignRetrospective study.SettingsPrivate veterinary teaching hospital.AnimalsThirty‐six dogs hospitalized in ICU receiving ProcalAmine between October 2010 and March 2013.InterventionsNone.Measurements and Main ResultsThe most common underlying disease process in this population of dogs was trauma (n = 8). Median duration of administration was 4 days and median resting energy requirement provided via ProcalAmine was 33%. ProcalAmine was administered via central catheters in 86% of cases and via peripheral catheters in 14% of cases. The overall mechanical complication rate was 19%. Metabolic complications possibly associated with ProcalAmine administration were documented in 12/36 dogs. Hyponatremia was most commonly identified (n = 6) followed by hyperglycemia (n = 4), hypochloremia (n = 2), azotemia (n = 2), metabolic alkalosis (n = 2), hyperchloremia (n = 1), and metabolic acidosis (n = 1).ConclusionProcalAmine appears to be relatively safe and a viable option for parenteral nutrition in ill and injured dogs. Due to the potential for electrolyte derangements and other metabolic complications, daily monitoring of these parameters is advisable.

01 May 2012·Pain Medicine

Behcet's Disease (Syndrome) with Myalgia and Its Response to 3% Amino Acids and 3% Glycerin

Letter

Author: Thomas Bryan

Dear Editor: You published a case series for me in Pain Medicine 2011; 12:1414–1417. In the reports that I mentioned, I emphasized amino acids as the cause of their quick and robust response with treatment. During these treatments, the amino acids that were available at the hospital consisted of 3% glycerol and 3% amino acids. In the meantime, Medicare has decided that these kinds of cases should be treated as an outpatient. Also, the hospital that I use has discontinued this combination of Procalamine …

01 Sep 2011·Pain MedicineQ3 · MEDICINE

Behcet's Disease (Syndrome) with Myalgia and Its Response to Intravenous Amino Acids: A Case Series

Q3 · MEDICINE

Article

Author: Bryan, Thomas

OBJECTIVETo present a case series of patients with refractory Behçet's disease who presented with myalgia and with signs such as mouth and genital ulcerations and skin lesions and were treated with intravenous amino acids.DESIGN AND SETTINGCase series of patients with Behçet's Disease who presented to a clinical practice devoted to Pain Medicine and Neurology between 2000 and 2009 for treatment of myalgia.METHODSAll patients were treated with prednisone 60 mg by mouth daily for exacerbations of their disease. When this failed, eleven patients received intravenous administration of amino acids (Procalamine).RESULTSTen of eleven patients had a complete resolution of their Behçet's exacerbation, including myalgia; their painful ulcers became painless and began to heal with the infusion of amino acids for 2-5 days.CONCLUSIONPhysicians treating myalgia should observe for signs of Behçet's disease, such as oral and genital ulcerations, and consider intravenous amino acids if steroids are not effective.

100 Deals associated with Amino acids/calcium acetate/glycerin/magnesium acetate/phosphoric acid/potassium chloride/sodium acetate/sodium chloride

R&D Status

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Amino acids/calcium acetate/glycerin/magnesium acetate/phosphoric acid/potassium chloride/sodium acetate/sodium chloride

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation